Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer
ROCKVILLE, MARYLAND, August 18, 2022 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced that the first patient has been enrolled in its Phase I trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC).…